Brookstone Capital Management
ANIK icon

Brookstone Capital Management’s Anika Therapeutics ANIK Stock Holding History

Brookstone Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-10,835
Closed -$409K – 447
2020
Q2 		$409K Buy
+10,835
New +$357K 0.03% 258

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return

Brookstone Capital Management's ANIK Position: Q3 2020 in Review

Brookstone Capital Management sold out of Anika Therapeutics (ANIK) in Q3 2020, closing a stake of 10,835 shares — an estimated $409K sold.

Brookstone Capital Management first reported a position in ANIK in Q2 2020 and held it in 1 quarter. The position peaked at $409K in Q2 2020. 156 funds tracked by Wall St. Rank hold ANIK as of Q3 2020.

  • Brookstone Capital Management reported no remaining Anika Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Brookstone Capital Management sold 10,835 Anika Therapeutics shares in Q3 2020, an estimated $409K.
  • Brookstone Capital Management first reported a position in Anika Therapeutics in Q2 2020 and held it in 1 quarter.
  • Brookstone Capital Management's Anika Therapeutics position peaked at $409K in Q2 2020.
  • 156 funds tracked by Wall St. Rank held Anika Therapeutics as of Q3 2020.

Based on Brookstone Capital Management's 13F filing for Q3 2020, filed 13 Oct 2020.